RevolKa completed the contract research with SEKISUI CHEMICAL CO., LTD

Tokyo Japan- Jul 17, 2024. RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (Norio Hamamatsu, CEO) completed the contract research with SEKISUI CHEMICAL CO., LTD. (Keita Kato, President & Representative Director) (https://www.revolka.com/news/english/collab-en/a53). RevolKa successfully provided high-performance protein candidates by using our proprietary protein engineering platform technology, called aiProtein®: a robust directed protein evolution technology integrated with artificial intelligence (AI).